Quality of life decrements in men with prostate cancer undergoing androgen deprivation therapy

• Published in: Clinical endocrinology (Oxford) 2017-03, Vol.86 (3), p.388-394
• Main Authors: Cheung, Ada S., Rooy, Casey, Hoermann, Rudolf, Lim Joon, Daryl, Zajac, Jeffrey D., Grossmann, Mathis
• Format: Article
• Language: English
• Subjects: Aged; Androgen Antagonists - therapeutic use; Case-Control Studies; Exercise; Humans; Male; Middle Aged; Prospective Studies; Prostatic Neoplasms - psychology; Quality of Life; Sexual Dysfunction, Physiological; Surveys and Questionnaires
• ISSN: 0300-0664; 1365-2265
• DOI: 10.1111/cen.13249

Summary Objective While androgen deprivation therapy (ADT) has been associated with decreased quality of life (QoL), controlled prospective studies are lacking. We aimed to assess QoL during ADT using two validated questionnaires and determine contributing factors. Design Prospective controlled study. Patients Sixty‐three men with nonmetastatic prostate cancer newly commencing ADT (n = 34) and age‐ and radiotherapy‐matched prostate cancer controls (n = 29). Measurements QoL was measured by Short‐Form 12 version 2 survey (SF‐12) and Aging Males’ Symptoms (AMS) score at 0, 6 and 12 months. Generalized linear models determined the mean adjusted difference (MAD) (95% confidence interval) between groups during follow‐up. Results Compared to controls over 12 months, men receiving ADT had decreased SF‐12 physical component score [MAD −3·61 (−6·94, −0·29), P = 0·013] reflecting worsening QoL but no change in the mental component (P = 0·74). Total AMS score increased [MAD 9·35 (5·65, 13·07), P